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market and capitation reimbursement for general practitioners and pediatricians
were widely accepted. Incentive payments for both the above specialties were
approved and determined according to the home visits for the pediatricians and
according to the number of the enrolled elderly and chronic condition patients, the
carry out of screening and the home visits for the general practitioners. Per-item
reimbursement for specialists was weakly supported. The introduction of an inter-
nal market along with global budgets and incentive payments was argued that
could control expenditure and supplier-induced demand, and improve equity in
access and outcomes. CONCLUSIONS: Experts argue that a public monopsony in
Greece can hardly guarantee efficiency and effectiveness, unless included in a
wider reform framework of prospective payments, market-like mechanisms and
financial incentives.
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OBJECTIVES: Early Access Programmes (EAPs) provide the possibility of making
medicines that address an unmet medical need available to patients before regu-
latory approval from the competent authorities. Market Access includes market
development activities and patient access strategy, EAPs can positively impact
both areas. The aim of this review is to consider, compile and describe the main
EAPs available in Non-European Countries.METHODS:We conducted a review and
performed a mapping of EAPs systems that exists in Europe. We searched existing
literature in Embase, National Health Systems Website, ISPOR conference websites
and Internet. In the countries where information were more scattered we directly
contacted regulatory agencies and clinicians familiar with the local EAP regula-
tions and practices.RESULTS:We described the practical implications surrounding
the regulatory framework for EAPs, the key stakeholders involved in EAP decision-
making and administration, the timelines for EAPs approval, and the key factors for
success. Many countries do not have an EAP in place and compassionate use is the
only route to market for unregistered or investigational products. This is the case
for Russia, Turkey, South Korea, Israel, India, and Brazil. The markets where EAP
are more developed and sales are possible are: South Africa, Canada and Australia.
CONCLUSIONS: This project made specific recommendations on the most favour-
able countries, based on the ease of setting up such a programme and the potential
revenue that could result.
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OBJECTIVES: The national government is repositioning the Community Pharma-
cies (CP) in the national health service, through definition of different: mix of ser-
vices, relation with other health care actors, and range of objectives to achieve.
Considering the contextual factors, the paper aims at analyzing the managerial
implication for CP. For this purpose the CPs’ director strategic attitude and the
structure of the information system are investigated. METHODS: The paper is
based on literature review and on a survey conducted among a national sample of
695 community pharmacies (CP). Data were collected through a questionnaire or-
ganized in both open questions and closed questions (Likert scale 1-7). Data were
analyzed according to descriptive statistics to support the qualitative study ap-
proach. The SPSS program was used. RESULTS: Respondents have limited aware-
ness of the different actions that the national and regional contexts implement
regard to the CP. Although, the mix of services provided is heterogeneous and not
widely consistent with the aims of the government reform (2009 law decree), there
is a positive willingness to extent the professional role. Increasing the mix of ser-
vices provided is perceived a strategic action (m5,09), services are delivered even
if the contribution to the CP’s revenues is very low (m2,62). The information
system allows the monitoring of the overall financial results (m5,33), while its
relevance decreases with regard to the CP’s cost structure (m4,5) and to the spe-
cific service/business area’s contribution to the general results (m4,18).
CONCLUSIONS: The study suggests that CP’s directors haven’t developed an effec-
tive strategic orientation yet. The actual information system is not able to support
them to manage the changes. As long as CPs’ director develop a strategic orienta-
tion, they could act as agent of change.
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OBJECTIVES: Understand country-specific evidence requirements for the national
reimbursement of orphan products (disease prevalence: 5/10,000) in the UK,
France, Spain, Italy and Germany. METHODS: Qualitative research identified
guidelines for reimbursement submission from each national reimbursement
body. 1–5 orphan product appraisals per country were also reviewed to gain insight
into the application of guidelines. Findings are based only on review of the guide-
lines and selected appraisals. RESULTS: The markets studied do not have reim-
bursement processes specifically for orphan products, however special consider-
ations exist. For example, while direct comparator trials are the preferred sources
of clinical evidence for non-orphan products, in certain instances reimbursement
of orphan products has been granted based on placebo-controlled trials accompa-
nied by indirect treatment comparisons. In England, exemptions are made only for
orphan products which extend survival in patients with short life expectancies. In
Scotland, 62% of decisions on orphan indications have been negative, mostly due to
a lack of robust economic evidence. In Italy, access to orphan products is encour-
aged and 94% of those launched are reimbursed: a lower benefit-risk ratio and
evidence outside randomized controlled trials is accepted for orphan products. In
France, orphan products benefit from fast-track procedures; however no special
evidence considerations are acknowledged. Under AM-NutzenV in Germany, the
medical benefit of orphan products is considered confirmed through the marketing
authorisation; thus orphan submissions require a limited submission document.
Whilst no national practices for orphan products exist in Spain, some regions
implement risk-sharing agreements. CONCLUSIONS: Whilst reimbursement bod-
ies recognize data limitations and provide special considerations for orphan prod-
ucts, processes are not explicit and requirements vary, leading to uncertainty in
the reimbursement evidence requirements. It is therefore important to engage
with appropriate reimbursement bodies to fully determine their specific require-
ments and modify one’s submission to demonstrate an orphan product’s ability to
meet payers’ needs.
PHP111
FACTORS PREDICTING REIMBURSEMENT DECISIONS ON ORPHAN DRUGS IN
EIGHT COUNTRIES
Kanters T, Redekop W, Hakkaart L
Erasmus University Rotterdam, Rotterdam, The Netherlands
OBJECTIVES: The number of orphan drugs has increased vastly over the last years.
However, the reimbursement of orphan drugs remains a black box. The objective of
this study was to examine how much reimbursement decisions are influenced by
disease-related and financial aspects of orphan drugs. METHODS: We examined
publicly available reimbursement decisions for all 11 orphan drugs listed on the
Dutch policy rule in eight countries (Australia, Belgium, Canada, England, Ireland,
New Zealand, Scotland, and Wales). We examined whether the proportion of pos-
itive reimbursement decisions (based on the originally submitted price) depended
on number of eligible patients, treatment costs, budget impact or timing of appli-
cation. Information on these factors were based on the Dutch situation. RESULTS:
For these 11 orphan drugs, 45 reimbursement decisions were publicly available, of
which 12 decisions were positive. In addition, three decisions were positive for only
a subgroup of an indication (infantile Pompe disease) and negative for all other
patients (late-onset Pompe disease). Furthermore, in two cases the orphan drug
was not eligible for reimbursement at the originally submitted price. One decision
was deferred to allow additional data collection. The proportion of positive reim-
bursement decisions decreased as treatment cost per patient increased. A similar
relationship was observed between total budget impact and proportion of positive
reimbursement decisions. The number of eligible patients did not influence the
proportion of positive reimbursement decisions. The proportion of positive deci-
sions was lower for orphan drugs that were added to the policy rule at a later time.
CONCLUSIONS: The proportion of positive reimbursement decisions is lower for
drugs with higher treatment costs or budget impact. Future studies should be
conducted with country-specific explanatory factors. Furthermore, future research
should not only examine the outcomes of reimbursement decisions, but also study
the entire reimbursement process to identify areas of improvement.
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OBJECTIVES: To develop a quantitative process to estimate the probability of a
favorable assessment of additional clinical benefit for a new drug for a chronic
non-life threatening disease in Germany METHODS: A multi-criteria decision pro-
cess was use that included: selection of 7 German decision makers; pre-workshop
questionnaires to identify the most important attributes for the decision and their
relative importance; a workshop to develop levels for the most important attri-
butes, map each attribute level to a value function and identify marginal drug
profiles (drugs just demonstrating ‘additional clinical benefit’); post-workshop es-
timation of weighted scores for each marginal product based on the estimated
values and relative importance of their attribute levels and a logistic regression
model to estimate the probability of an ‘additional clinical benefit’ decision as a
function of the weighted scores; post-workshop questionnaire to validate the lo-
gistic regression model using participant ratings for some hypothetical products.
RESULTS: The most important attributes identified for a determination of ‘addi-
tional clinical benefit’ and their relative importance weights (%) were: robustness of
clinical evidence (29%); incremental efficacy (19%); unmet need (12%); incremental
impact on QOL (10%); availability of alternative treatments (9%); safety of new drug
(9%); burden of disease (5%); availability of other country evaluations (4%); budget
impact (3%). The attribute levels and relative value for a positive decision (0-1) for
the most important attribute, robustness of clinical evidence, were: ‘endpoints
and/or comparators not relevant to patients’ (0); ‘clinical endpoints relevant but
comparators not relevant needing indirect comparisons’ (0.764); and ‘all clinical
endpoints and comparators relevant for patients and payers (1)’. The estimates of
the probability of an ‘additional clinical benefit’ for the hypothetical products using
the logistic regression model had 71% positive predictive value and 85% negative
predictive value when compared to participant decisions for these hypothetical
products. CONCLUSIONS: An MCDA process can provide both a qualitative under-
standing and quantitative estimates of the relative importance, attribute levels,
and value scales of different product attributes that influence a decision of ‘addi-
tional clinical benefit’ in Germany.
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